scholarly journals ASAP1 promotes tumor cell motility and invasiveness, stimulates metastasis formation in vivo, and correlates with poor survival in colorectal cancer patients

Oncogene ◽  
2010 ◽  
Vol 29 (16) ◽  
pp. 2393-2403 ◽  
Author(s):  
T Müller ◽  
U Stein ◽  
A Poletti ◽  
L Garzia ◽  
M Rothley ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Tumor Cell ◽  
Cell Motility ◽  
Cancer Patients ◽  
Metastasis Formation ◽  
Poor Survival ◽  
Tumor Cell Motility ◽  
Colorectal Cancer Patients

High Expression of sLex Associated with Poor Survival in Argentinian Colorectal Cancer Patients

2014 ◽  
Vol 29 (1) ◽  
pp. e30-e39 ◽  
Author(s):  
Ariel Zwenger ◽  
Martin Rabassa ◽  
Sandra Demichelis ◽  
Gabriel Grossman ◽  
Amada Segal-Eiras ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Lymph Nodes ◽  
Cancer Patients ◽  
Normal Mucosa ◽  
Poor Survival ◽  
Primary Tumors ◽  
Metastatic Lymph Nodes ◽  
Metastatic Lymph ◽  
Colorectal Cancer Patients

Aim Colorectal cancer (CRC) is one of the most prevalent malignancies in Argentina with 11,043 new cases and 6,596 deaths estimated to have occurred in 2008. The present study was developed to clarify the differential expression of MUC1, MUC2, sLex, and sLea in colorectal cancer patients and their relationship with survival and clinical and histological features. Methods Ninety primary tumor samples and 43 metastatic lymph nodes from CRC patients were studied; follow-up was documented. Twenty-six adenoma and 68 histological normal mucosa specimens were analyzed. An immunohistochemical approach was applied and statistical analysis was performed. Results In tumor samples, MUC1, sLea, and sLex were highly expressed (94%, 67%, and 91%, respectively); also, we found a significantly increased expression of the 3 antigens in primary tumors and metastatic lymph nodes compared with normal mucosa and adenomas. MUC2 was expressed in 52% of both normal mucosa and CRC samples; this reactivity significantly decreased in metastatic lymph nodes (p<0.05). A multiple comparison analysis showed that MUC1 and sLex discriminated among 3 groups: normal, adenoma, and CRC tissues. The increase of sLex expression showed an association with recurrence, and survival analysis showed that a high sLex staining was significantly associated with a poor survival. By multivariate analysis MUC1 inmunoreactivity correlated positively and significantly with tumor size, while MUC2 expression showed the opposite correlation. Conclusions The correlation of sLex overexpression in primary tumors and metastatic lymph nodes, the discrimination among the normal, adenoma, and CRC groups based on sLex expression, as well as its association with recurrence and survival, all suggest a prognostic role of sLex in Argentinian CRC patients.

Preoperative Vascular Endothelial Growth Factor Levels as a Prognostic Marker for Stage II or III Colorectal Cancer Patients

2011 ◽  
Vol 4 ◽  
pp. CGM.S7113 ◽  
Author(s):  
Ozgur Kemik ◽  
Ahu Sarbay Kemik ◽  
Aziz Sümer ◽  
Sevim Purisa ◽  
A. Cumhur Dulger ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Cancer Patients ◽  
Elevated Serum ◽  
Stage Ii ◽  
Vascular Endothelial ◽  
Poor Survival ◽  
Colorectal Cancer Patients ◽  
Endothelial Growth Factor

Background The aim of the present study was to determine whether serum vascular endothelial growth factor (VEGF) can provide prognostic information independent of carcinoembryonic antigen levels in patients undergoing curative surgery. Methods Serum samples were collected from 158 patients with colorectal cancer and from 100 controls. Serum and tissue levels of VEGF were measured by enzyme-linked immunosorbent assay. Serum VEGF levels in colorectal cancer patients were compared with those in healthy controls, and we retrospectively assessed the association between serum VEGF levels and clinicopathologic findings and survival. Results VEGF expression was significantly higher in colorectal cancer tissue compared with nontumor tissue. Mean serum VEGF levels in patients were significantly higher than those in controls, and significantly higher in patients with large tumors, lymph node involvement, and distant metastases. Conclusion Elevated serum VEGF was significantly associated with poor survival, but was only an independent risk factor for poor survival in Stage II and/or III disease. Elevated serum VEGF is significantly associated with development of colorectal cancer, and lymph or distant invasive phenotypes and survival, especially in Stage II and III patients.

SU-GG-T-05: MOSFET In-Vivo Dosimetry for Colorectal Cancer Patients Treated with Shielded Brachytherapy

2008 ◽  
Vol 35 (6Part8) ◽  
pp. 2727-2727
Author(s):  
C Furstoss ◽  
X Yan ◽  
B Reniers ◽  
E Poon ◽  
A Hallil ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
In Vivo Dosimetry ◽  
Colorectal Cancer Patients

scholarly journals P-146 A genetic custom-made in vivo drug screening platform for colorectal cancer patients

2020 ◽  
Vol 31 ◽  
pp. S137
Author(s):  
C. de Miguel ◽  
A. Chai ◽  
A. Sawala ◽  
L. Towart ◽  
N. Villegas
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Drug Screening ◽  
Custom Made ◽  
Screening Platform ◽  
Colorectal Cancer Patients ◽  
Made In

In vivo biological effects of panitumumab + chemotherapy in advanced colorectal cancer patients

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 14576-14576 ◽  
Author(s):  
K. Bencardino ◽  
M. Ronzoni ◽  
M. Manzoni ◽  
B. Rovati ◽  
S. Mariucci ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Advanced Colorectal Cancer ◽  
Biological Effects ◽  
Colorectal Cancer Patients

scholarly journals High MACC1 expression in combination with mutated KRAS G13 indicates poor survival of colorectal cancer patients

2015 ◽  
Vol 14 (1) ◽  
pp. 38 ◽  
Author(s):  
Katharina Ilm ◽  
Wolfgang Kemmner ◽  
Marc Osterland ◽  
Susen Burock ◽  
Gudrun Koch ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Poor Survival ◽  
Colorectal Cancer Patients

Elevated serum VEGF levels in colorectal cancer patients correlate with poor survival

2001 ◽  
Vol 37 ◽  
pp. S304 ◽  
Author(s):  
A. Karayiannakis ◽  
K. Syrigos ◽  
A. Zbar ◽  
N. Baibas ◽  
D. Tsioulos ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Elevated Serum ◽  
Poor Survival ◽  
Colorectal Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document